Q32 Bio Inc. (NASDAQ:QTTB)
| Market Cap | $249.57M+317.0% |
| Revenue (ttm) | $53.74M |
| Net Income | $32.25M+176.6% |
| EPS | $3.13+162.1% |
| Shares Out | 29.92M |
| PE Ratio | 2.66 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 476,717 |
| Open | $8.37 |
| Previous Close | $8.48 |
| Day's Range | $8.22 - $8.57 |
| 52-Week Range | $1.98 - $23.57 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $36.50(+337.65%) |
| Earnings Date | Mar 9, 2027 |
About QTTB
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 9, 2027Earnings report
$QTTB stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in QTTB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by QTTB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
QTTB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New QTTB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to QTTB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in QTTB
| VTIVanguard Morningstar Total Stock Market ETF | $5.30M |
| AVUVAvantis U.S. Small Cap Value ETF | $4.48M |
| VXFVanguard Extended Market ETF | $2.07M |
| FDMFirst Trust Dow Jones Select MicroCap Index Fund | $746.67K |
| DFASDimensional - US Small Cap ETF | $346.81K |
| AVSCAvantis U.S. Small Cap Equity ETF | $293.31K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from QTTB’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-36.0 since Aug 28Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
